Glucokinase activators for the potential treatment of type 2 diabetes.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Current Topics in Medicinal Chemistry

• Publication date

  2008-10-31

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.2174/156802608786413483PMID 19075763
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Glucose modulation of glucokinase activation by small molecules

  2008cited by this paper
• Sugar binding to recombinant wild-type and mutant glucokinase monitored by kinetic measurement and tryptophan fluorescence.

  2008cited by this paper
• Glucokinase activators in diabetes management

  2008cited by this paper
• Catalytic activation of human glucokinase by substrate binding – residue contacts involved in the binding of D‐glucose to the super‐open form and conformational transitions

  2008cited by this paper
• Glucokinase and molecular aspects of liver glycogen metabolism.

  2008cited by this paper
• Glucose-Dependent Modulation of Insulin Secretion and Intracellular Calcium Ions by GKA50, a Glucokinase Activator

  2007cited by this paper
• Glucokinase activator PSN-GK1 displays enhanced antihyperglycaemic and insulinotropic actions

  2007cited by this paper
• A pre-steady state analysis of ligand binding to human glucokinase: evidence for a preexisting equilibrium.

  2007cited by this paper
• An Allosteric Activator of Glucokinase Impairs the Interaction of Glucokinase and Glucokinase Regulatory Protein and Regulates Glucose Metabolism*

  2006cited by this paper
• The network of glucokinase-expressing cells in glucose homeostasis and the potential of glucokinase activators for diabetes therapy.

  2006cited by this paper
• Conformational transition pathway in the allosteric process of human glucokinase

  2006cited by this paper
• Glucose-induced conformational changes in glucokinase mediate allosteric regulation: transient kinetic analysis.

  2006cited by this paper
• Predictive blood glucose lowering efficacy by Glucokinase activators in high fat fed female Zucker rats

  2006cited by this paper
• Biochemical Basis of Glucokinase Activation and the Regulation by Glucokinase Regulatory Protein in Naturally Occurring Mutations*

  2006cited by this paper
• Metabolic sensing neurons and the control of energy homeostasis.

  2006cited by this paper
• Design of a potent, soluble glucokinase activator with excellent in vivo efficacy.

  2006cited by this paper
• A Glucose Sensor Role for Glucokinase in Anterior Pituitary Cells

  2006cited by this paper
• The regulation of glucose effectiveness: how glucose modulates its own production

  2005cited by this paper
• Glucokinase-activating ureas.

  2005cited by this paper
• A novel glucokinase activator modulates pancreatic islet and hepatocyte function.

  2005cited by this paper
• Global prevalence of diabetes: estimates for the year 2000 and projections for 2030.

  2004cited by this paper
• Stimulation of hepatocyte glucose metabolism by novel small molecule glucokinase activators.

  2004cited by this paper
• Structural basis for allosteric regulation of the monomeric allosteric enzyme human glucokinase.

  2004cited by this paper
• Allosteric Activators of Glucokinase: Potential Role in Diabetes Therapy

  2003cited by this paper
• Fructose improves the ability of hyperglycemia per se to regulate glucose production in type 2 diabetes.

  2002cited by this paper
• Glucokinase gene locus transgenic mice are resistant to the development of obesity-induced type 2 diabetes.

  2001cited by this paper
• Effects of type 2 diabetes on the ability of insulin and glucose to regulate splanchnic and muscle glucose metabolism: evidence for a defect in hepatic glucokinase activity.

  2000cited by this paper
• Characterization of Glucokinase Regulatory Protein-deficient Mice*

  2000cited by this paper
• Mice mutant for glucokinase regulatory protein exhibit decreased liver glucokinase: a sequestration mechanism in metabolic regulation.

  1999cited by this paper
• Impaired hepatic glycogen synthesis in glucokinase-deficient (MODY-2) subjects.

  1996cited by this paper
• Liver Glucokinase: Decreased Activity in Patients with Type II Diabetes

  1995cited by this paper
• Short-term regulation of glucokinase.

  1994cited by this paper
• Enzyme memory. 1. A transient kinetic study of wheat-germ hexokinase LI.

  1977cited by this paper
• Metabolism of glucose in the islets of Langerhans.

  1968cited by this paper
• HEPATIC GLUCOKINASE ACTIVITY IN HUMAN DIABETICS AND NONDIABETICS.

  1964cited by this paper

• Insights to the emerging potential of glucokinase activators as antidiabetic agent.

  2024cites this paper
• Identification of small-molecule glucokinase activator for type-2-diabetes treatment: a structure-based virtual screening approach

  2023cites this paper
• In silico docking based screening of constituents from Persian shallot as modulators of human glucokinase

  2022cites this paper
• Recifin A, Initial Example of the Tyr-Lock Peptide Structural Family, Is a Selective Allosteric Inhibitor of Tyrosyl-DNA Phosphodiesterase I.

  2020cites this paper
• Recent Developments in Medicinal Chemistry of Allosteric Activators of Human Glucokinase for Type 2 Diabetes Mellitus Therapeutics.

  2020cites this paper
• Molecular Dynamics Simulations and Kinetic Measurements to Estimate and Predict Protein-Ligand Residence Times.

  2016cites this paper
• Detection of secondary binding sites in proteins using fragment screening

  2015cites this paper
• Atherogenic, fibrotic and glucose utilising actions of glucokinase activators on vascular endothelium and smooth muscle

  2014cites this paper
• C5-Alkyl-2-methylurea-Substituted Pyridines as a New Class of Glucokinase Activators.

  2014cites this paper
• Discovery of 2-pyridylureas as glucokinase activators.

  2014cites this paper
• Small molecule disruptors of the glucokinase-glucokinase regulatory protein interaction: 1. Discovery of a novel tool compound for in vivo proof-of-concept.

  2014cites this paper
• Role of connecting loop I in catalysis and allosteric regulation of human glucokinase

  2014cites this paper
• Recent updates on glucokinase activators for the treatment of type 2 diabetes mellitus.

  2014cites this paper
• Preclinical PK/PD modeling and human efficacious dose projection for a glucokinase activator in the treatment of diabetes

  2014cites this paper
• Current Status Glucokinase Regulation : History and A Fresh View of Glycolysis and Minireviews

  2014cites this paper
• A Fresh View of Glycolysis and Glucokinase Regulation: History and Current Status*

  2014cites this paper
• Antidiabetic effects of glucokinase regulatory protein small-molecule disruptors

  2013cites this paper
• A phospho-BAD BH3 helix activates glucokinase by a mechanism distinct from that of allosteric activators

  2013influential citation
• A report of 2 new cases of MODY2 and review of the literature: implications in the search for type 2 diabetes drugs.

  2013cites this paper
• QSAR studies of novel potent benzamide derivatives as glucokinase activators

  2013cites this paper
• Dose selection using a semi-mechanistic integrated glucose-insulin-glucagon model: designing phase 2 trials for a novel oral glucokinase activator

  2013cites this paper
• Small-Molecule Allosteric Activation of Human Glucokinase in the Absence of Glucose.

  2013cites this paper
• Enantioselective synthesis of tatanans A-C and reinvestigation of their glucokinase-activating properties.

  2013cites this paper
• The design and synthesis of indazole and pyrazolopyridine based glucokinase activators for the treatment of type 2 diabetes mellitus.

  2012cites this paper
• Novel phenyl-urea derivatives as dual-target ligands that can activate both GK and PPARγ

  2012cites this paper
• Design, synthesis, and pharmacological evaluation of benzamide derivatives as glucokinase activators.

  2012cites this paper
• Discovery of novel dual-action antidiabetic agents that inhibit glycogen phosphorylase and activate glucokinase.

  2012cites this paper
• Glucokinase activation repairs defective bioenergetics of islets of Langerhans isolated from type 2 diabetics.

  2012influential citation
• Human pancreatic glucokinase. Structural and physico-chemical studies related to catalytic activation, kinetic cooperativity and GCK-diabetes.

  2012cites this paper
• Human pancreatic glucokinase

  2012cites this paper
• Novel Pharmacological Approaches to the Treatment of Type 2 Diabetes

  2012influential citation
• Current therapies and emerging drugs in the pipeline for type 2 diabetes.

  2011cites this paper
• N-(5-substituted thiazol-2-yl)-2-aryl-3-(tetrahydro-2H-pyran-4-yl) propanamides as glucokinase activators

  2011cites this paper
• urcumin diminishes the impacts of hyperglycemia on the activation of hepatic tellate cells by suppressing membrane translocation and gene expression of lucose transporter-2

  2011cites this paper
• Pharmacokinetic and Pharmacodynamic Properties of the Glucokinase Activator MK-0941 in Rodent Models of Type 2 Diabetes and Healthy Dogs

  2011cites this paper
• Glucokinase Activation Repairs Defective Bioenergetics of Islets of Langerhans isolated from 1 Type-2-Diabetics 2 3

  2011influential citation
• Discovery and hit-to-lead optimization of novel allosteric glucokinase activators.

  2011cites this paper
• The active conformation of human glucokinase is not altered by allosteric activators.

  2011cites this paper
• Curcumin prevents leptin raising glucose levels in hepatic stellate cells by blocking translocation of glucose transporter‐4 and increasing glucokinase

  2010cites this paper
• Glucokinase activation induces potent hypoglycemia without recruiting insulin and inhibits food intake in chicken.

  2010cites this paper
• A small-molecule glucokinase activator lowers blood glucose in the sulfonylurea-desensitized rat.

  2010cites this paper
• Piragliatin (RO4389620), a novel glucokinase activator, lowers plasma glucose both in the postabsorptive state and after a glucose challenge in patients with type 2 diabetes mellitus: a mechanistic study.

  2010cites this paper
• Novel therapeutics and targets for the treatment of diabetes

  2010cites this paper
• Highly enantioselective hydrogenation of alpha-aryl-beta-substituted acrylic acids catalyzed by Ir-SpinPHOX.

  2010cites this paper
• Diabetes Drugs: Present and Emerging

  2010cites this paper
• [New classes of drugs in the pipeline. New in the treatment of diabetes mellitus].

  2010cites this paper
• Discovery, structure-activity relationships, pharmacokinetics, and efficacy of glucokinase activator (2R)-3-cyclopentyl-2-(4-methanesulfonylphenyl)-N-thiazol-2-yl-propionamide (RO0281675).

  2010cites this paper
• Genetics in gestational diabetes mellitus: association with incidence, severity, pregnancy outcome and response to treatment.

  2010cites this paper
• Design, synthesis, and pharmacological evaluation of N-(4-mono and 4,5-disubstituted thiazol-2-yl)-2-aryl-3-(tetrahydro-2H-pyran-4-yl)propanamides as glucokinase activators.

  2010cites this paper
• Pharmacological Targeting of the Mitochondrial Phosphatase PTPMT1

  2010cites this paper
• Pyridones as glucokinase activators: identification of a unique metabolic liability of the 4-sulfonyl-2-pyridone heterocycle.

  2009cites this paper
• Recent advances in glucokinase activators for the treatment of type 2 diabetes.

  2009cites this paper
• The design and optimization of a series of 2-(pyridin-2-yl)-1H-benzimidazole compounds as allosteric glucokinase activators.

  2009cites this paper
• Glucokinase in pancreatic b-cells and liver parenchymal cells : a target for

  2009cites this paper
• Direct small-molecule kinase activation: Novel approaches for a new era of drug discovery.

  2009cites this paper
• Update on mutations in glucokinase (GCK), which cause maturity‐onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemic hypoglycemia

  2009cites this paper
• Glucokinase activators: Novo Nordisk's WO2008084044 and Array Biopharma's WO2008091770

  2009cites this paper
• Investigation of functionally liver selective glucokinase activators for the treatment of type 2 diabetes.

  2009cites this paper
• Therapeutic targets to reduce cardiovascular disease in type 2 diabetes

  2009cites this paper
• Medicinal chemistry approaches for glucokinase activation to treat type 2 diabetes.

  2009cites this paper
• Structure-activity relationships of 3,5-disubstituted benzamides as glucokinase activators with potent in vivo efficacy.

  2009cites this paper